Michael Aberman joins Regeneron

Former Wall Street analyst joins firm at pivotal time

US biotechnology firm Regeneron Pharmaceuticals has appointed Michael Aberman as vice president of strategy and investor relations. Peter Dworkin, vice president, will continue to be responsible for corporate communications.

Prior to joining Regeneron, Aberman spent six years as a Wall Street research analyst covering the biotechnology industry. Most recently, he was director and senior biotechnology analyst at Credit Suisse and before that, vice president and biotech analyst at Morgan Stanley. Before moving to Wall Street, Aberman was director of business development at Antigenics, an oncology-focused biotechnology company.

‘I am very excited to be joining Regeneron at a pivotal time in its history,’ said Aberman. ‘2010 will bring results from multiple Phase III trials in gout, age-related macular degeneration, and cancer. In addition, the expanded collaboration with Sanofi-Aventis positions Regeneron to capitalise on its capabilities to build a robust pipeline of antibody-based product candidates over the coming years.’

You may also like

Pharmaceutical

Sanofi and Regeneron restructures immuno-oncology collaboration

The companies announce selection of two pipeline projects to continue collaboration while independently pursuing other programmes
Media

GlobalData names top 25 global pharma companies by market cap

The performance highlights of the top 25 publicly traded global pharma companies for the year 2017 have been confirmed in the latest research from GlobalData
Regulatory

Sanofi and Regeneron announce Marketing Authorisation Application for Dupixent (dupilumab) accepted for review by the EMA

Sanofi and Regeneron Pharmaceuticals, Inc.  today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application (MAA) for Dupixent® (dupilumab) for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy
Design & Build

Regeneron to create 200 new jobs as it invests US$350m in Limerick, Ireland

Firm is currently upgrading a former Dell Computer site into the largest capacity bulk biologics production facility in the region
Research & Development

Pipeline advancements and asset acquisitions fuelled mid-cap biotech R&D spend in 2014

Combined R&D spend of 35 mid-cap biotech companies increased by nearly US$2bn to reach a total of $9.7bn in 2014
Manufacturing

Roquette opens pharmaceutical innovation centre in Brazil

The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing

Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours

The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Subscribe now